Although the reasons for the limited clinical efficacy of IL-12 in cancer patients is not fully understood [8,15,28], several immunosuppressive mechanisms, including CD4+ Treg cell accumulation due to increased IL-10 production and diminished IFN-γ production after repetitive treatments with IL-12, could be involved [17,29,30]. The gene discussed is IFNG; the disease is cancer.